Proxalutamide

普克鲁胺

Report date: 2026/04/15 20:02:38
NME

Base Information

Drug NameProxalutamide
Drug Alias NameGT-0918
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAndrogen Receptor antagonists
TargetsAndrogen Receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerProstatic Neoplasms, Castration-Resistant +[5] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryParaguay
Original Approved Date2021/07/16
Country/TerritoryUnited StatesUkraineParaguay +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Koshine Biomedica IncChina Pharmaceutical University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdPT Etana Biotechnologies IndonesiaSuzhou Koshine Biomedica Inc +[4] 
Inactive CompaniesApplied Biology IncCorpometria Institute
Active IndicationsCoronavirus Disease 2019 (COVID-19)Prostatic Neoplasms, Castration-ResistantBreast Neoplasms
Inactive IndicationsMetastatic breast cancerSevere Acute Respiratory Syndrome

Other Information

ATC CodeN/A
Related LinksWikipedia